Skip to main content

Table 4 Survival times of patients with or without extramedullary manifestations who received allogeneic hematopoietic stem cell transplantation

From: Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Survival times of patients who received HCT

EM AML

Non-EM AML

Hazard ratio

Cox regression p-value

Event-free survival

9.8 [6.7–14.8]

10.7 [9.1–13.2]

0.98 [0.73–1.33]

0.910

Relapse-free survival

13.0 [8.2–37.5]

16.3 [12.7–20.0]

0.99 [0.72–1.38]

0.975

Overall survival

30.8 [18.2–54.2]

72.1 [48.7–103.7]

1.29 [0.93–1.80]

0.130

  1. Survival times for AML patients with and without extramedullary manifestations (EM) that received allogeneic hematopoietic cell transplantation (HCT, n = 573, 36.20%) are shown. Survival times in months. Cox-proportional hazard models were used to obtain univariable hazard ratios. Brackets show 95%-confidence intervals